Form 4: Celldex Therapeutics Director Acquires Stock Options

Cheryl Cohen, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, under the company's 2021 Omnibus Equity Incentive Plan.

Summary

• On June 17, 2024, a Form 4 filing with the SEC revealed that Cheryl Cohen, a director of Celldex Therapeutics, Inc., acquired 16,500 non-qualified stock options.
• The transaction occurred on June 13, 2024, at an exercise price of $36.43 per share.
• These options, representing the right to buy common stock, were granted under the company's 2021 Omnibus Equity Incentive Plan.
• The options are exercisable starting June 13, 2025, and expire on June 13, 2034.
• Following the transaction, Cheryl Cohen directly owns 16,500 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing regarding stock option grants, which is generally neutral. It indicates ongoing compensation practices.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The 2021 Omnibus Equity Incentive Plan is being utilized to incentivize key personnel.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grant.

Key Dates